Clinical TrialTreatment-Resistant Depression (TRD)KetaminePlaceboRecruiting

Intravenous Ketamine for Treatment-Resistant Depression (G2K)

Randomised, triple-blind, placebo-controlled, parallel-group Phase II trial (n=30) comparing single IV ketamine 0.5 mg/kg versus saline infusion in adults with treatment-resistant depression; primary outcomes include central and peripheral GABA and glutamate changes and change in MADRS at 24 hours.

Target Enrollment
30 participants
Study Type
Phase II interventional
Design
Randomized, triple Blind

Detailed Description

Adults with treatment-resistant major depressive disorder will be randomised 1:1 to a single 40-minute IV racemic ketamine infusion (0.5 mg/kg) or normal saline in an MRI scanner; an optional open-label ketamine infusion is offered 1–7 days later.

Primary analyses relate peak central GABA and glutamate measured by sliding-window fMRS during infusion to peripheral GABA and glutamate changes by LC–MS from baseline to 24 hours, and to change in MADRS.

Study Protocol

Preparation

sessions

Dosing

1 sessions
40 min each

Integration

sessions

Study Arms & Interventions

Ketamine Group

experimental

Single IV racemic ketamine infusion 0.5 mg/kg (max 50 mg cap for >100 kg)

Interventions

  • Ketamine0.5 mg/kg
    via IV• single infusion• 1 doses total

    40-min infusion; optional open-label ketamine 1–7 days after initial treatment; max 50 mg cap for >100 kg

Normal Saline

inactive

Normal saline 40-min IV infusion (placebo comparator)

Interventions

  • Placebo
    via IV• single infusion• 1 doses total

    Normal saline 40-min infusion; participants may receive optional open-label ketamine 1–7 days later

Participants

Ages
18 – 65
Sexes
Male & Female

Inclusion Criteria

  • Inclusion Criteria:
  • Ability to provide informed consent
  • Meets diagnostic criteria for major depressive disorder without psychotic features per the SCID DSM-IV-TR
  • PHQ-9 total score ≥ 15 at screening
  • Treatment-resistant depression, as defined by failure of at least two previous antidepressant treatments within the current depressive episode. Failed antidepressant treatments can include pharmacotherapy for depression at an adequate dose for at least 8 weeks, trial of transcranial magnetic stimulation (TMS) or an acute series of at least 6 administrations of electroconvulsive therapy (ECT)
  • Ability to pass a comprehension assessment test related to effects of ketamine and trial objectives and criteria

Exclusion Criteria

  • Exclusion Criteria:
  • Inability to speak English
  • Inability to provide consent or have a legal guardian
  • Patients with a BMI > 40 kg/m2.
  • Personality disorder being the primary diagnosis
  • Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or active psychotic symptoms
  • Active post-traumatic stress disorder symptoms based on clinical assessment
  • Ongoing prescription of > 2 mg lorazepam equivalents (total) daily, or morning dosing of any benzodiazepine at the time of assessment
  • Medications known to affect glutamate (i.e., Riluzole, Carbamazepine) or GABA (zaleplon, zolpidem, zopiclone, Valproate, Gabapentin, Pregabalin, tiagabine, and vigabatrin) are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug
  • Monoamine Oxidase Inhibitors (MAOIs) are prohibited two weeks prior to administration of study drug
  • Opioid antagonists (naltrexone, naloxone, nalmefene, methylnaltrexone, buprenorphine and naloxone combination) are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug
  • CYP3A4 inducers carbamazepine and modafinil are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study drug.
  • Currently undergoing TMS, vagal nerve stimulation, or deep brain stimulation as either an acute or maintenance treatment of depression
  • ECT in the past 6 months
  • Any active or unstable medical condition judged by the study psychiatrist as conferring too great a level of medical risk to allow inclusion in the study
  • A history of bleeding in the brain
  • Arteriovenous malformation or a history of aneurysm
  • Use of methamphetamine, cocaine, or cannabis. Abuse of stimulant(s) within the prior 12 months
  • Any current substance use disorder (excluding nicotine and caffeine). Note: Persons will be allowed to enroll in this study if their substance use is in complete (not partial) and sustained (> 1 year) remission
  • History of traumatic brain injury that resulted in loss of consciousness with brain bleeding
  • History of tonic-clonic (grand mal) seizures
  • Developmental delay, intellectual disability, or intellectual disorder
  • Clinical or self-reported diagnosis of delirium, encephalopathy, or related clinical diagnosis within the prior 12 months
  • Minor or Major Neurocognitive disorder
  • Received ketamine treatment for depression within the prior 2 months
  • History of either poor antidepressive response to or poor tolerability of ketamine (any route of administration) when previously administered
  • History of hypothyroidism unless taking a stable dose of thyroid medication and asymptomatic for 3 months
  • Hepatic insufficiency (2.5 X ULN for AST or ALT) within 3 months of consent, past liver transplant recipient, and/or clinical diagnosis of cirrhosis of the liver
  • Gastroesophageal reflux disease that is poorly managed
  • A diagnosis of Complex Regional Pain Syndrome (CRPS)
  • Pregnancy, or nursing
  • History of claustrophobia with active symptoms that would interfere with the MRI
  • Any contraindication to MRI safety questionnaire
  • Poorly controlled hypertension.

Study Details

Locations

Mayo Clinic in Rochester — Rochester, Minnesota, United States

Your Library